- Home
- DHY vs CRBP Comparison
DHY vs CRBP Comparison
Compare DHY & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DHY | CRBP |
|---|---|---|
| Founded | 1998 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.2M | 170.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DHY | CRBP |
|---|---|---|
| Price | $2.00 | $7.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $50.29 |
| AVG Volume (30 Days) | ★ 569.1K | 492.2K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 9.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.77 | $4.64 |
| 52 Week High | $2.08 | $20.56 |
Technical Indicators
Market Signals| Indicator | DHY | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 46.57 | 28.92 |
| Support Level | $1.98 | $7.97 |
| Resistance Level | $2.03 | $8.54 |
| Average True Range (ATR) | 0.02 | 0.47 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 49.67 | 5.21 |
Price Performance
Historical ComparisonAbout DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.